Researchers have identified a potential treatment strategy for Rett syndrome via alternative splicing modulation of the MECP2 gene.
The vehicles that deliver gene editing cargo to the body’s cells can be toxic, complicating gene therapies, particularly those addressed to brain cells of developing fetuses. Less toxic carriers, ...
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results